Squarepoint
BDTX icon

Squarepoint’s Black Diamond Therapeutics BDTX Stock Holding History

Squarepoint’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,280
Closed -$32.5K – 4410
2026
Q1 		$32.5K Buy
15,280
+528
+4% +$1.26K ﹤0.01% 4165
2025
Q4 		$35.8K Sell
14,752
-2,429
-14% -$8.6K ﹤0.01% 4145
2025
Q3 		$65.1K Sell
17,181
-66,295
-79% -$194K ﹤0.01% 4187
2025
Q2 		$207K Buy
83,476
+61,018
+272% +$118K ﹤0.01% 3961
2025
Q1 		$34.8K Sell
22,458
-109,416
-83% -$229K ﹤0.01% 4394
2024
Q4 		$282K Buy
131,874
+72,688
+123% +$208K ﹤0.01% 4198
2024
Q3 		$257K Buy
59,186
+33,835
+133% +$184K ﹤0.01% 3552
2024
Q2 		$118K Sell
25,351
-146,025
-85% -$784K ﹤0.01% 3764
2024
Q1 		$869K Buy
171,376
+26,524
+18% +$107K ﹤0.01% 2688
2023
Q4 		$407K Buy
+144,852
New +$340K ﹤0.01% 3158
2022
Q1 		– Sell
-18,674
Closed -$100K – 2826
2021
Q4 		$100K Sell
18,674
-1,418
-7% -$9.91K ﹤0.01% 2914
2021
Q3 		$170K Buy
+20,092
New +$198K ﹤0.01% 2546
2021
Q2 		– Sell
-59,863
Closed -$1.45M – 3223
2021
Q1 		$1.45M Buy
59,863
+29,429
+97% +$794K 0.01% 1263
2020
Q4 		$975K Buy
+30,434
New +$1,000K 0.01% 1354

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Squarepoint's BDTX Position: Q2 2026 in Review

Squarepoint sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 15,280 shares — an estimated $32.5K sold.

Squarepoint first reported a position in BDTX in Q4 2020 and held it in 14 quarters. The position peaked at $1.45M in Q1 2021. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Squarepoint reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 15,280 Black Diamond Therapeutics shares in Q2 2026, an estimated $32.5K.
  • Squarepoint first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 14 quarters.
  • Squarepoint's Black Diamond Therapeutics position peaked at $1.45M in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.